Bilateral fumarate hydratase deficient renal cell carcinoma in a patient with hereditary leiomyomatosis and renal cell cancer syndrome.
fumarate hydratase
hereditary leiomyomatosis and cancer
nephrectomy
renal cell
renal cell carcinoma
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
20
09
2023
accepted:
17
12
2023
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
5
3
2024
Statut:
epublish
Résumé
Patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome have high risks of uterine and cutaneous leiomyomas and renal cell carcinoma (RCC), which are caused by germline mutation of the fumarate hydratase (FH) gene. RCC lesions are mostly high-grade tumors with a poor prognosis. A 37-year-old man who had previously undergone treatment for a left RCC was referred to our hospital with a diagnosis of right RCC. Robot-assisted partial nephrectomy was performed, and the pathological diagnosis revealed fumarate hydratase (FH)-deficient RCC. The left RCC, which was originally diagnosed as mucinous tubular and spindle cell carcinoma, was reviewed and diagnosed as FH-deficient RCC. The patient's father and uncle both died of RCC, and the father's tumor was also immunohistochemically proven to be FH-deficient RCC. HLRCC-related RCC should be considered in a differential diagnosis of young patients with a family history of RCC.
Identifiants
pubmed: 38440695
doi: 10.1002/iju5.12688
pii: IJU512688
pmc: PMC10909150
doi:
Types de publication
Case Reports
Langues
eng
Pagination
144-147Informations de copyright
© 2024 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.
Déclaration de conflit d'intérêts
None of the contributing authors has any conflicts of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.